Clarithromycin

Active ingredient: Clarithromycin

1 This product can slightly increase the blood concentration of carbamazepine. When the two are used together, the latter's blood concentration needs to be monitored. 2 This product has a slight effect on the metabolism of aminophylline and theophylline in the body. Generally, there is no need to adjust the dosage of the latter, but the blood concentration needs to be monitored when the dosage of aminophylline and theophylline is too high. 3 Similar to other macrolide antibiotics, this product will increase the serum concentration of drugs that need to be metabolized by the cytochrome P450 system (such as astemizole, warfarin, ergot alkaloids, triazolam, midazolam, cyclosporine, omeprazole, ranitidine, phenytoin, bromocriptine, alfentanil, hexobical, disopyramide, lovastatin, tacrolimus, etc.). 4 When used in combination with HMGCoA reductase inhibitors (such as lovastatin and simvastatin), there are very few reports of rhabdomyolysis. 5. Combination with cisapride and pimozide will increase the blood concentration of the latter, leading to QT interval prolongation and arrhythmias such as ventricular tachycardia, ventricular fibrillation and congestive heart failure. Combination with astemizole will lead to QT interval prolongation, but without any clinical symptoms. 6. Macrolide antibiotics can change the metabolism of terfenadine and increase its blood concentration, leading to arrhythmias such as ventricular tachycardia, ventricular fibrillation and congestive heart failure. 7. Combination with digoxin will cause an increase in digoxin blood concentration, and blood drug concentration monitoring should be performed. 8. When HIV-infected adults take this product and zidovudine orally at the same time, this product will interfere with the absorption of the latter and cause its steady-state blood concentration to decrease, so the time of administration should be staggered. 9. When used in combination with ritonavir, the metabolism of this product will be significantly inhibited. Therefore, when the daily dose of this product is greater than 1g, it should not be used in combination with ritonavir. 10. Combination with fluconazole will increase the blood concentration of this product.

Main ingredients: The main ingredient of this product is clarithromycin, its chemical name is 6-O-methylerythromycin. Molecular formula: C38H69NO13 Molecular weight: 747.96

1 This product can slightly increase the blood concentration of carbamazepine. When the two are used together, the latter's blood concentration needs to be monitored. 2 This product has a slight effect on the metabolism of aminophylline and theophylline in the body. Generally, there is no need to adjust the dose of the latter, but the blood concentration needs to be monitored when the dose of aminophylline and theophylline is too high. 3 Similar to other macrolide antibiotics, this product will increase the serum concentration of drugs that need to be metabolized by the cytochrome P450 system (such as astemizole, warfarin, ergot alkaloids, triazolam, midazolam, cyclosporine, omeprazole, ranitidine, phenytoin, bromocriptine, alfentanil, hexobical, disopyramide, lovastatin, tacrolimus, etc.). 4 This product is used in combination with HMG-CoA reductase inhibitors (such as lovastatin and simvastatin), and there are very few reports of rhabdomyolysis. 5. The combination of this product with cisapride and pimozide will increase the blood concentration of the latter, leading to Q-T interval prolongation and arrhythmias such as ventricular tachycardia, ventricular fibrillation and congestive heart failure. The combination with astemizole will lead to Q-T interval prolongation, but without any clinical symptoms. 6. Macrolide antibiotics can change the metabolism of terfenadine and increase its blood concentration, leading to arrhythmias such as ventricular tachycardia, ventricular fibrillation and congestive heart failure. 7. The combination of this product with digoxin will cause an increase in digoxin blood concentration, and blood drug concentration monitoring should be performed. 8. When HIV-infected adults take this product and zidovudine orally at the same time, this product will interfere with the absorption of the latter and cause its steady-state blood concentration to decrease, so the time of taking should be staggered. 9. The metabolism of this product will be significantly inhibited when used in combination with ritonavir. Therefore, when the daily dose of this product is greater than 1g, it should not be used in combination with ritonavir. 10. The blood concentration of this product will increase when used in combination with fluconazole.

Clarithromycin.

1. This product can slightly increase the blood concentration of carbamazepine. When the two are used together, the latter's blood concentration needs to be monitored. 2. This product has a slight effect on the metabolism of aminophylline and theophylline in the body. Generally, there is no need to adjust the dosage of the latter, but the blood concentration needs to be monitored when the dosage of aminophylline and theophylline is too high. 3. Similar to other macrolide antibiotics, this product will increase the serum concentration of drugs that need to be metabolized by the cytochrome P450 system (such as astemizole, warfarin, ergot alkaloids, triazolam, midazolam, cyclosporine, omeprazole, ranitidine, phenytoin, bromocriptine, alfentanil, hexobical, disopyramide, lovastatin, tacrolimus, etc.). 4. This product is used in combination with HMGCoA reductase inhibitors (such as lovastatin and simvastatin). There are very few reports of rhabdomyolysis. 5. The combination of this product with cisapride and pimozide will increase the blood concentration of the latter, leading to QT interval prolongation and arrhythmias such as ventricular tachycardia, ventricular fibrillation and congestive heart failure. The combination with astemizole will lead to QT interval prolongation, but without any clinical symptoms. 6. Macrolide antibiotics can change the metabolism of terfenadine and increase its blood concentration, leading to arrhythmias such as ventricular tachycardia, ventricular fibrillation and congestive heart failure. 7. The combination of this product with digoxin will cause an increase in digoxin blood concentration, and blood drug concentration monitoring should be performed. 8. When HIV-infected adults take this product and zidovudine orally at the same time, this product will interfere with the absorption of the latter and cause its steady-state blood concentration to decrease, so the time of taking should be staggered. 9. The metabolism of this product will be significantly inhibited when used in combination with ritonavir, so this product should not be used in combination with ritonavir when the daily dose is greater than 1g. 10. The blood concentration of this product will increase when used in combination with fluconazole.